RNS Number : 8128G
Immupharma PLC
30 November 2020
RNS | eCorporate 30 November 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
Total Share Capital Notification
ImmuPharma PLC (LSE:IMM), (Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company announces that in accordance with its obligations to the Company's Euronext listing and following an application of Article 15 of the Belgian Law of 2 May 2007, the total number of shares with voting rights and the total number of voting rights are set out below:
|
Situation as at 30 November 2020
|
|
|
|
1. Information to be provided for on the basis of Article 15, §1, al. 1
|
|
|
|
Total of share capital (nominal value)
|
:
|
£ 25,022,129
|
|
|
|
|
|
Total number of shares with existing voting rights (= denominator) - one vote per share
|
:
|
250,221,297
|
|
|
|
|
|
2. Additional information to be provided on the basis of Article 15, §1, al. 2
In respect to the announcement on 11 June 2020: "Investment from two specialist US healthcare investors"
|
|
|
|
|
|
|
|
Convertible Securities (in whole or in part) into ordinary shares currently outstanding.
The total conversion would result in an equal number of voting rights
|
:
|
6,493,506
|
|
|
|
|
|
Share options (in whole or in part)
The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights
|
:
|
25,640,254
|
|
In respect to the announcements on 30 March 2020: "Subscription to raise £1.5m" and 2 September 2020 "Placing to raise £6.5m"
|
|
|
|
|
|
|
|
Warrants over ordinary shares (in whole or in part)
The exercise of the warrants would result in the creation of an equal number of ordinary shares and voting rights
In respect to the announcement on 26 November 2020: "Grant of options and PDMR Dealing"
Share options (in whole or in part)
The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights
|
:
:
|
3,343,045
9,625,000
|
|
|
|
|
|
|
|
|
|
Other outstanding rights to subscribe ordinary shares as detailed in the Annual Report 2019 (Report and consolidated financial Statements for the year ended 31 December 2019)
|
|
|
|
|
|
|
|
Share options (in whole or in part)
The exercise of the options would result in the creation of an equal number of ordinary shares and voting rights
|
:
|
16,368,850
|
|
|
|
|
This situation (the denominator) serves as a basis for the notification of major holdings by shareholders.
|
For further information please contact:
|
ImmuPharma PLC (
www.immupharma.co.uk
)
Tim McCarthy, Chairman
|
+ 44 (0) 207 152 4080
|
|
Dimitri Dimitriou, Chief Executive Officer
|
|
|
Lisa Baderoon, Head of Investor Relations
|
+ 44 (0) 7721 413496
|
|
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes
SI Capital (Joint Broker)
Nick Emerson
|
+44 (0)
20
3 36
8 3550
+44 (0) 203 815 8880
+44 (0) 1483 413500
|
|
4Reliance (Euronext Growth Listing Sponsor)
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider)
Erik De Clippel
Backstage Communication
Olivier Duquaine
Gunther De Backer
|
+32 (0) 2 747 02 60
+32 (0) 2 287 95 34
+32 (0) 477 504 784
+32 (0) 475 903 909
|
|
|
|
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase III for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase III trial for Lupuzor™ and commercialise in the US.
For additional information about ImmuPharma please visit
www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
TVRBUBDBGUDDGGR
|
